Liquid Biopsy for Proliferative Diabetic Retinopathy: Single-Cell Transcriptomics of Human Vitreous Reveals

Rachana Haliyur1, David H Parkinson2, Feiyang Ma3

  • 1Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan.

Ophthalmology Science
|September 2, 2024
PubMed
Abstract

Insights

This study reveals that T cells dominate the vitreous of proliferative diabetic retinopathy (PDR) patients, unlike neutrophils. These findings highlight unique immune cell activity in PDR, offering new therapeutic targets for vision loss.

Area of Science:

  • Ophthalmology
  • Immunology
  • Genomics

Background:

  • Current proliferative diabetic retinopathy (PDR) treatments lack specificity for VEGF-independent inflammatory pathways driving vision loss.
  • Understanding the cellular and molecular mechanisms of PDR is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify targetable cell types and signaling pathways in PDR by analyzing the single-cell transcriptomic landscape of the vitreous.
  • To characterize the immune cell composition and activation states within the vitreous of PDR patients.

Main Methods:

  • Single-cell RNA sequencing (scRNA-seq) was performed on vitreous cells and peripheral blood mononuclear cells (PBMCs) from PDR patients.
  • Transcriptomic data were analyzed to identify cell types, differential gene expression, and ligand-receptor interactions.

Main Results:

  • Vitreous samples were predominantly composed of T cells (91.6%), with distinct T cell populations (CD4+, CD8+, Tregs) and activated memory T cells observed.
  • Neutrophils were virtually absent in the vitreous, contrasting with their presence in peripheral blood.
  • Unique ligand-receptor interactions within the vitreous microenvironment were identified.

Conclusions:

  • PDR vitreous is characterized by a unique T cell-dominant immune environment, distinct from peripheral blood.
  • The study demonstrates the feasibility of using liquid vitreous biopsies for mechanistic and therapeutic insights into PDR.
  • These findings pave the way for novel, targeted therapies for PDR-associated vision loss.